INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Biohaven Ltd. (BHVN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Biohaven Ltd. alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit specifically claims that the regulatory prospects of troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder were overstated [1] - The lawsuit suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [1] Legal Context - Shareholders who purchased Biohaven shares between March 24, 2023, and May 14, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 12, 2025 [3] - Holzer & Holzer, LLC is representing shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]